MDR modulation in acute myelogenous leukemia: Is it dead?

Leukemia

Volumn 15, Issue 4, 2001, Pages 666-667

  Karp, J E ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; PSC 883; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TRANSPORT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; MOLECULAR CLONING; MULTIDRUG RESISTANCE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0035073481     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402055     Document Type: Review

References (6)

1. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high risk AML: A Southwest Oncology Group (SWOG) study
2. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid Cancer and Leukemia Group B Study 9420
3. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group Study 9617
4. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
5. Novel mechanisms of drug resistance in leukemia
6. P-glyco-protein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells